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Background: Colchicine has unique anti-inflammatory properties that may be beneficial in various
cardiovascular conditions. This systematic review and meta-analysis of randomized controlled trials (RCTs)
examines this issue.
Methods: We searched MEDLINE, EMBASE, and the Cochrane Database from inception to June 2014 for RCTs
using colchicine in adult patients with cardiac diseases. Results were pooled using random effects.
Results: 15 RCTs (n = 3431 patients, median treatment 3 and follow-up 15 months) were included. All but 2
used colchicine 1 mg/day. In 5 trials, n = 1301) at risk for cardiovascular disease (coronary artery disease,
acute coronary syndrome or stroke, post-angioplasty [2 RCTs], or congestive heart failure), colchicine
reduced composite cardiovascular outcomes by ~60 % (risk ratio [RR] 0.44, 95 % confidence interval [CI]
0.28-0.69, p = 0.0004; I2 = 0 %) and showed a trend towards lower all-cause mortality (RR 0.50, 95 % CI
0.23-1.08, p = 0.08; I2 = 0 %). In pericarditis or post-cardiotomy, colchicine decreased recurrent pericarditis
or post-pericardiotomy syndrome (RR 0.50, 95 % CI 0.41-0.60, p < 0.0001; I2 = 0 %; 8 RCTs, n = 1635), and
post-pericardiotomy or ablation induced atrial fibrillation (RR 0.65, 95 % CI 0.51-0.82, p = 0.0003; I2 = 31 %;
4 RCTs, n = 1118). The most common adverse event was diarrhea. Treatment discontinuation overall and
due to adverse events (RR 4.34, 95 % CI 1.70-11.07, p = 0.002; I2 = 29 %; 7 RCTs, 83/790 [10.5 %] vs. 11/697
[1.6 %]) was higher in colchicine-assigned patients.
Conclusions: Current RCT data suggests that colchicine may reduce the composite rate of cardiovascular
adverse outcomes in a range of patients with established cardiovascular disease. Furthermore, colchicine
reduces rates of recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation
following cardiac surgery. Further RCTs evaluating the potential of colchicine for secondary prevention of
cardiovascular events would be of interest.
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Colchicine is used to treat gout and other inflammatory
diseases such as familial Mediterranean fever and Behçet’s
syndrome [1–6]. Randomized controlled trials (RCTs) have
evaluated colchicine in a wide spectrum of cardiac disease
[7]. There is now tantalizing evidence that it may prove to
be a useful adjunct to current therapy in the treatment and
prevention of pericarditis, post procedural atrial fibrillation,
atherosclerosis, and stent related disease. In addition, new
insights into the role of cholesterol crystal-induced,
neutrophil-mediated inflammation in atherosclerosis add
plausibility to the clinical benefits observed with its use in
secondary prevention of cardiovascular disease [8, 9]. Con-
sequently, we set out to conduct a meta-analysis of RCTs to
evaluate the benefits of colchicine in patients with both cor-
onary artery and other cardiac diseases.
Methods
Data sources
We systematically searched OVID versions of MEDLINE
(1946 through to July 2014, week 1), EMBASE Classic and
EMBASE (1947 through 2014 week 28), and the Cochrane
Central Register of Controlled Trials (Issue 5, June 2014)
for relevant studies using “colchicine” and “coronary artery”
or “cardiovascular” search terms, and previously-published
sensitive filters to identify randomized controlled trials
(RCTs) [10, 11] (see Fig. 1 for detailed search strategy). We
also searched bibliographies of included studies and per-
sonal files. We did not impose language restrictions.
Study selection
We included prospective clinical trials randomizing pa-
tients to colchicine vs. placebo or no therapy. Eligible
studies included adult patients with cardiac disease in-
cluding cardiovascular disease, cardiomyopathy or con-
gestive heart failure, pericardial disease, or arrhythmias.
Studies were excluded if patients were not randomized
between treatment groups. Citations were screened and
full text review was conducted to determine eligibility
when a screening reviewer felt a citation potentially met
inclusion criteria.
Data extraction and quality assessment
Details of the publication (i.e. trial authors and acronym,
enrolment period, year of publication), inclusion/exclusion
criteria, demographics and cardiac risk factors of the en-
rolled patients, description of the interventions used, and
outcome definitions and events were collected and collated.
Risk of bias in RCTs (including blinding of participants,
method of sequence generation and allocation conceal-
ment, intention-to-treat analysis, early trial stopping for ef-
ficacy before the planned enrollment was completed, and
loss to follow-up) was also assessed.Data analysis
The primary outcome was the composite cardiovascular
outcome as defined by each RCT enrolling patients with
cardiovascular diseases, and was recurrent pericarditis or
post-pericardiotomy syndrome for RCTs enrolling pa-
tients with pericarditis or post pericardiotomy. (Given
the different cardiac diseases in the included trials, we
only pooled data for trials enrolling patients with rele-
vant conditions for each outcome). Secondary outcomes
were all-cause mortality, acute coronary syndrome or
non-fatal myocardial infarction, revascularization, and
non-fatal stroke (cardiovascular disease trials); and ar-
rhythmias (pericarditis, post-pericardiotomy syndrome,
and post radiofrequency ablation trials). Adverse events,
and treatment discontinuation data were pooled from all
trials as we felt these may be independent of patient
condition and to provide the most robust estimate of
overall adverse event rates. All analyses were performed
using Review Manager (RevMan version 5.2; Cochrane
Collaboration, Oxford, UK). Random effects models
[12] which incorporate between-trial heterogeneity
and give wider and more conservative confidence in-
tervals (CI) when heterogeneity is present were used
for all analyses. Statistical heterogeneity among trials
was assessed using the I2 statistic, defined as the per-
centage of total variability across studies attributable
to heterogeneity rather than chance, and using pub-
lished guidelines for low (I2 = 25 %-49 %), moderate
(I2 = 50 %–74 %) and high (I2 ≥ 75 %) heterogeneity
[13]. Relative risks (RR) were used to pool outcomes
with a two-sided significance level of 5 %. Individual
trial and summary results are reported with 95 % CIs.
For the pericarditis RCTs, we use Z-tests of interaction to
calculate interaction p-values comparing RRs between
separate subgroups (e.g. acute pooled RR vs. recurrent
pericarditis pooled RR, etc.). To assess for publication
bias, a funnel plot comparing effect measure to study pre-
cision was examined for evidence of asymmetry.
Results
The initial search strategy yielded 287 citations from
MEDLINE and EMBASE, and 315 citations from
Cochrane, of which 24 were retrieved for full text review.
Fifteen RCTs enrolling 3431 patients met inclusion criteria
(Fig. 1). Five RCTs measured cardiovascular outcomes in
patients with cardiovascular disease including stable cor-
onary artery disease (CAD) [14]. acute coronary syndrome
or stroke [15]. post-angioplasty with balloon [16] or bare
metal stents [7]. and stable congestive heart failure [17].
Five RCTs enrolled patients with either acute pericarditis
[18, 19], recurrent pericarditis [20, 21], or multiply
recurrent pericarditis [22]. Four RCTs enrolled patients
post-cardiac surgery pericardiotomy [23–26], and 1 RCT
post-radiofrequency ablation for atrial fibrillation [27].
Fig 1. Search Strategy and Trial Flow. Flow chart for the systematic review and meta-analysis showing the search strategy, and the number of
studies retained and number of studies excluded with reason for exclusion at each stage of the study selection process. For description of
excluded studies see Table 5
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lished in two publications [28, 29].
Description of included studies and quality assessment
All but 2 RCTs used a colchicine dose of 1 mg/day.
Almost half the trials, mainly those enrolling patients with
pericarditis [18–22] or post cardiac surgery [24, 25], re-
duced the dose to 0.5 mg/day in patients with signs of
medication intolerance or body weight <70 kg. Median
treatment duration was 3 months. Patient follow-up
ranged from 7 days to 3 years (median 15 months).
Tables 1 and 2 provide details of the RCTs including
baseline patient characteristics. For the 5 pericarditisRCTs [18–22] mean age was lower (range 48–57 years
old) and a lower proportion were male (range 35-60 %)
compared to the non-pericarditis RCTs (mean age 57–68
years old, and proportion male 65-89 %). For the non-
pericarditis RCTs, patients had expected prevalence of
various coronary risk factors including hypertension,
diabetes, dyslipidemia and smoking. Previous myocar-
dial infarction or coronary artery disease ranged from
7-40 % in the 7 RCTs that provided this information
[14, 15, 21–24, 27]. Patients with congestive heart
failure were generally not enrolled except for the one
RCT that specifically enrolled such patients [17]. All
trials excluded patients with severe renal failure.
Table 1 Trial and Baseline Patient Characteristics, and Interventions of RCTs Measuring Cardiovascular Outcomes
Stable CAD ACS (91 %) or
Acute Stroke (9 %)
Post Successful Elective
Balloon PTCA
Post BMS PTCA in
DM (31 % ACS)
Symptomatic stable CHF
with LVEF≤ 40 %
Colchicine Dose 0.5 mg/d 1 mg/d 0.5 mg bid 0.5 mg bid 0.5 mg bid
Trial Nidorf 2013 [14] Raju 2012 [15] O’Keefe 1992 [16] Deftereos 2013 [7] Deftereos 2014 [17]
N = 532 N = 80 N = 197 N = 222 N = 267
Trial Characteristics
No. Centres 1 1 1 1 1
Enrolment period Aug 2008 – May
2010
Apr 2008 – Aug
2009
n/r n/r n/r
Treatment/Follow Up 2 (all)/3 (median) yrs 32 days (median) 5.5 months (mean) 6 months (?all) 6 months (all)
Funding None Public n/r n/r n/r
Patients N = 532 N = 80 N = 197 N = 196 N = 279
Mean Age (years) 66 57 60 64 67
% Male 89 % 88 % 86 % 65 % 67 %
BMI 27 26
Diabetes 31 % 16 % 12 % 100 % 17 %
HTN 42 % 49 % 36 %
Smoker 5 % 44 % 38 %
Dyslipidemia 48 % Total Chol 211 mg/dL 33 %
Prev MI/UA 23 % 18 %
Prev stroke/TIA 4 %
PVD 5 %








Mean LVEF 56 % 28 %
Previous CABG 19 % (Prev PCI 58 %) 26 %
Medications
ASA and/or clopidogrel 93 % (DAPT 12 %) 100 % (DAPT 85 %)
Statin 95 % 98 % 63 %
Beta-Blocker 67 % 79 %
Calcium Channel Blocker 14 %
ACE Inhibitor 58 % 85 % (incl ARB)
Diuretic 69 %
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(Table 3). All but three trials [14, 18, 20] were blinded
using placebos and in one of these three non-placebo
controlled RCTs, outcome assessors were blinded [14].
Allocation was specified to be concealed in the 7 trials
that reported this information [14, 15, 19, 21, 22, 24, 25].
Thirteen trials specified that intention-to-treat analysis
[7, 14, 15, 17–25, 27] was used and thirteen trials
indicated that they were not stopped early for benefit
[7, 14–17, 19, 21–27]. Only one trial had >10 % of ran-
domized patients with missing outcome data [23]
though in two trials the proportion of excluded ran-
domized patients was unclear [16, 26].Quantitative data synthesis
Cardiovascular Outcomes: Colchicine was associated with a
>50 % reduction in the composite cardiovascular outcome
(RR 0.44, 95 % CI 0.28-0.69, p = 0.0004, I2 = 0 %; 5 trials
[1301 patients]) (Fig. 2). As indicated in Fig. 2, two of these
trials reported only deaths.[16, 17]. This result was
driven by the single-centre RCT in stable CAD which
was the only RCT to individually demonstrate a sta-
tistically significant benefit (RR 0.33, 95 % CI 0.19-
0.59, p = 0.0001; n = 532). It made up 65 % of the
weighting in the pooled estimate and included mor-
tality, myocardial infarction, stroke, and cardiac arrest
in its composite outcome [14]. This trial was open
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N = 120 N = 240 N = 84 N = 120 N = 240 N = 163 N = 360 N = 360 N = 216 N = 230
Trial
Characteristics


















































Funding Public Public Public Public Public n/r Public Public n/r n/r
Patients N = 120 N = 240 N = 84 N = 120 N = 240 N = 111 N = 360 N = 360 N = 216 N = 206
Mean Age
(years)
57 52 54 48 49 64 66 68 60 62
% Male 45 % 60 % 35 % 53 % 50 % 73 % 67 % 69 % 72 % 70 %
BMI 26 26
Diabetes 3 % 27 % 23 % 22 % 37 % 25 %
HTN 23 % 46 % 68 % 68 % 53 % 41 %
Smoker 49 % 48 % 13 % 29 % 30 % 35 %
Dyslipidemia 42 %











































Table 2 Trial and Baseline Patient Characteristics, and Interventions of RCTs in Pericarditis, Post-Pericardiotomy Syndrome and Post-RF Ablation for Arrythmia (Continued)
Previous
CABG











ACE Inhibitor 54 %
(incl ARB)
Diuretic
Abbreviations: ACE angiotensin converting enzyme, ACS acute coronary syndrome, ARB angiotensin receptor blocker, AFib atrial fibrillation, ASA acetylsalicylic acid (aspirin), bid twice daily, BMI body mass index, BMS
bare metal stent, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF congestive heart failure, chol cholesterol, Cr serum creatinine concentration, CrCl creatinine clearance, CRD chronic renal
disease, DAPT dual anti-platelet therapy, DM diabetes mellitus, dL deciliter, eGFR estimated glomerular filtration rate, excl excluded, h hour, HTN hypertension, kg kilogram (body weight), LVEF left ventricular ejective
fraction, mg milligram, μM micromolar, MI myocardial infarction, mL milliliter, N number of patients, no. number, n/r not reported, PCI percutaneous coronary intervention, POD post-operative day, prev previous, PTCA














Table 3 Quality assessment of included randomized controlled trials






<5 % Randomized Patients with
Missing Outcome Data




Yes Yes Yes Yes (0 %, 0/532)
Raju 2012 [15] 32 days (median) Yes Yes Yes Yes No (7.3 %, 6/82)
O’Keefe 1992 [16] 5.5 months (mean) Yes n/r n/r Yes Unclear (unsuccessful PTCA patients
excluded but randomized before PTCA)
Deftereos 2013 [7] 6 months (all) Yes n/r Yes Yes Yes (0 %, 0/222 [clinical outcomes])
Deftereos 2014 [17] 6 months (all) Yes n/r Yes Yes Yes (1.1 %, 3/279)
Finkelstein
2002 [23]
3 months (all) Yes n/r Yes Yes No (32 %, 52/163)
COPE 2005
(Imazio) [18]




















Yes Yes Yes Yes Yes (0 %)
COPPS 2010/1
(Imazio) [24, 28]
19 months (mean) Yes Yes Yes Yes Yes (0 %)
COPPS-2 2014
(Imazio) [25]
3 months (median) Yes Yes Yes Yes Yes (0 %)
Sarzaeem 2014 [26] 7 days (mean)
(hospital discharge)
Yes n/r n/r Yes Unclear (excluded patients unable to
tolerate enteral medications within





Yes n/r Yes Yes No (10 %, 24/230 [AFib recurrence];
6.1 %, 14/230 [adverse events])
Abbreviations: AFib atrial fibrillation, n/r not reported, PTCA percutaneous coronary angioplasty
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tients for a median of 3 years [14]. Visual inspection
of the funnel plot for this outcome showed no evi-
dence of asymmetry.
All-cause mortality rates were low with only 4 trials
having a total of 10 deaths in the colchicine groupFig. 2 Forest Plot for Composite Cardiovascular Outcome. Individual and p
randomized controlled trials (RCTs) enrolling patients with cardiovascular d
with 95 % CI were calculated using random-effects models. Weight refers t
treatment effect. Each square and horizontal line denotes the point estima
the diamond’s centre denotes the point estimate and width denotes the 9
components indicated for each RCT, except for Nidorf 2013 [14] also includ
confidence interval; CVA, cerebrovascular attack; IV, inverse variance; MI, myand 18 deaths in the control group with a non-
significant trend of benefit in the colchicine group
(RR 0.50, 95 % CI 0.23-1.08, p = 0.08; I2 = 0 %) (Fig. 3).
There were no differences in rates of acute coronary
syndrome or non-fatal myocardial infarction (RR 0.59,
95 % CI 0.09-3.90, p = 0.58; I2 = 46 %; 2 trials withooled risk ratios (RR) with 95 % confidence intervals (CI) for
iseases comparing colchicine to placebo or control. The pooled RRs
o the contribution of each study to the overall pooled estimate of
te and 95 % CI for each trial’s RR. The diamonds signify the pooled RR;
5 % CI. The composite cardiovascular outcome includes the
es cardiac arrests. Abbreviations: ACS, acute coronary syndrome; CI,
ocardial infarction; revasc, revascularization
Fig. 3 Forest Plot for All-Cause Mortality. Individual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for randomized controlled trials
(RCTs) enrolling patients with cardiovascular diseases comparing colchicine to placebo or control. [RCTs enrolling patients with pericarditis
[18–22], post-pericardiotomy syndrome [23–26], or post-RF ablation [27] are excluded. Only two of these RCTs [24, 25] reported any deaths: 2/169
vs. 2/167 patients [24], and 6/180 vs. 2/180 [25]. Including these RCTs does not significantly change the pooled result: RR 0.74, 95 % CI 0.37-1.49,
p = 0.40. The pooled RRs with 95 % CI were calculated using random-effects models. Weight refers to the contribution of each study to the overall
pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95 % CI for each trial’s RR. The diamonds
signify the pooled RR; the diamond’s centre denotes the point estimate and width denotes the 95 % CI
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for revascularization (RR 0.90, 95 % CI 0.62-1.30, p = 0.58;
I2 = 0 %; 2 trials with 42/204 vs. 29/163 events [7, 16], or
stroke (RR 0.41, 95 % CI 0.06-2.75, p = 0.36; I2 = 0 %; 2 tri-
als with 1/318 vs. 3/288 events [14, 15]. Risk of stroke
remained similar even including data from the recently
published post-cardiac surgery trial that reported 2/180
vs. 1/180 patients with stroke [25]. RR 0.76, 95 % CI
0.17-3.37, p = 0.71; I2 = 0 %; 3 trials with 3/498 vs. 4/
468 events.Fig. 4 Forest Plot for Pericarditis and Post Cardiac Surgery Pericardiotomy. Ind
randomized controlled trials (RCTs) comparing colchicine to placebo or
pericardiotomy. The pooled RRs with 95 % CI were calculated using ra
study to the overall pooled estimate of treatment effect. Each square a
each trial’s RR. The diamonds signify the pooled RR; the diamond’s cen
The decreases in risks were similar for pericarditis vs. pericardiotomy RC
also for acute vs. recurrent vs. multiple recurrent pericarditis RCTs withRecurrent Pericarditis or Post-Pericardiotomy Syn-
drome: Colchicine decreased rates of recurrent peri-
carditis or pericardiotomy syndrome (RR 0.50, 95 %
CI 0.41-0.60, p < 0.0001, I2 = 0 %; 8 RCTs, n = 1635)
(Fig. 4). Despite different pathophysiology, this de-
crease was similar comparing the pooled result from
the 3 post-pericardiotomy RCTs (RR 0.56, 95 % CI
0.42-0.76, p = 0.0001, I2 = 0 % [23–25] with the pooled
result from the 5 pericarditis RCTs (RR 0.46, 95 %
CI 0.36-0.58, p < 0.0001, I2 = 0 % [18–22]; interactionividual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for
control in patients with pericarditis or post cardiac surgery
ndom-effects models. Weight refers to the contribution of each
nd horizontal line denotes the point estimate and 95 % CI for
tre denotes the point estimate and width denotes the 95 % CI.
Ts (interaction p = 0.28), and, as described in the manuscript text,
non-significant interaction p-values for all comparisons
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the pooled results from the 2 RCTs enrolling patients with
acute pericarditis (RR 0.40, 95 % CI 0.24-0.66, p = 0.0004,
I2 = 0 % [18, 19]) with the pooled results from the 3 RCTs
enrolling patients with recurrent pericarditis (RR 0.48,
95 % CI 0.36-0.63, p < 0.0001, I2 = 0 % [20–22]; interaction
p = 0.56), and similar comparing the pooled results from
the 2 RCTs enrolling patients with a first recurrence
of pericarditis (RR 0.44, 95 % CI 0.29-0.66, p < 0.0001,
I2 = 0 % [20, 21] with the result of the RCT [22] en-
rolling patients with two or more recurrences of peri-
carditis (RR 0.51, 95 % CI 0.34-0.76, p = 0.0009;
interaction p = 0.62) with all trials showing a roughly
50 % decrease in pericarditis recurrence. Visual in-
spection of the funnel plot for this outcome showed
no evidence of asymmetry (results not shown).
Colchicine decreased atrial fibrillation post-CABG/peri-
cardiotomy (RR 0.63, 95 % CI 0.45-0.90, p = 0.01, I2 = 52 %;
3 RCTs, n = 912 [24–26] and post-ablation atrial fibrillation
(RR 0.63, 95 % CI 0.44-0.89, p = 0.009; 1 RCT, n = 206 [27]
by similar amounts (pooled RR 0.65, 95 % CI 0.51-
0.82, p = 0.0003, I2 = 31 %; 4 RCTs, n = 1118) (Fig. 5).
Adverse Events: The most common adverse event
was diarrhea. Pooled results from all RCTs that re-
ported rates of diarrhea and other gastrointestinal
side effects demonstrated a two-fold increase (RR
2.06, 95 % CI 1.56-2.72, p < 0.0001; 13 RCTs, 227/
1559 [14.6 %] vs. 83/1463 [5.7 %]) with some hetero-
geneity (I2 = 17 %) (Fig. 6). The pericarditis patient
trials [18–22] which reduced the dose of colchicine
for intolerance or low body weight (<70 kg) and en-
rolled generally younger patients (mean age 48–57),
showed no significant increase in gastrointestinal side
effects. This was different than the results from the
other trials which showed a doubling of gastrointes-
tinal side effects (interaction p = 0.01). However, in-
cluding data from all 7 RCTs that reduced the dose
of colchicine for intolerance or body weight <70 kg
[18–22, 24, 25], the increase in gastrointestinal sideFig. 5 Forest Plot for Atrial Fibrillation. Individual and pooled risk ratios (RR
(RCTs) comparing colchicine to placebo or control in patients post cardiac
recurrent atrial fibrillation. The pooled RRs with 95 % CI were calculated us
study to the overall pooled estimate of treatment effect. Each square and h
RR. The diamonds signify the pooled RR; the diamond’s centre denotes theeffects was smaller but still statistically significant (RR
1.56, 95 % CI 1.09-2.24, p = 0.01, I2 = 0 %; 7 RCTs,
74/762 [9.7 %] vs. 46/762 [6.0 %]), suggesting that
dose reduction by itself is not sufficient to eliminate
gastrointestinal side effects. Increases in other adverse
events were infrequent and not statistically different
between groups: neuromuscular side effects including
myalgia, myopathy, neuritis, or neuropathy (RR 1.65,
95 % CI 0.86-3.15, p = 0.13, I2 = 0 %; 9 RCTs, 23/1192
[1.9 %] vs. 12/1191 [1.0 %] [7, 14, 15, 17, 19, 21, 22,
24, 25]; rash or puritis (RR 1.22, 95 % CI 0.24-6.12,
p = 0.81, I2 = 0 %; 3 RCTs, 4/416 [1.0 %] vs. 2/355
[0.6 %] [14–16]; alopecia (RR 1.59, 95 % CI 0.36-6.97,
p = 0.54, I2 = 0 %; 7 RCTs, 4/1103 [0.4 %] vs. 2/1100
[0.2 %] [7, 14, 19, 21, 22, 24, 25, 27]; elevated liver
enzymes (RR 1.44, 95 % CI 0.51-4.09, p = 0.49, I2 = 0 %; 8
RCTs, 9/1009 [0.9 %] vs. 6/1006 [0.6 %] [7, 17, 19, 21, 22,
24, 25, 27] there were no reported cases of liver failure];
and myelotoxicity (0/507 [0.0 %] vs. 0/503 [0.0 %] [7, 17,
24, 27]. Serious or life-threatening adverse events were not
reported in any trial.
Treatment discontinuation overall (RR 1.85, 95 % CI
1.33-2.59, p = 0.0003, I2 = 25 %; 13 RCTs, 196/1567
[12.5 %] vs. 85/1472 [5.8 %]) and due to adverse events
(RR 4.34, 95 % CI 1.70-11.07, p = 0.002, I2 = 29 %; 7 RCTs,
83/790 [10.5 %] vs. 11/697 [1.6 %]) was higher with colchi-
cine (Fig. 7). This was the case even including data only
from the 7 RCTs that reduced the dose of colchicine
for intolerance or body weight <70 kg [18–22, 24,
25]: discontinuation overall, RR 1.40, 95 % CI 1.04-
1.89, p = 0.03, I2 = 0 %; 7 RCTs, 95/762 [12.5 %] vs.
64/762 [8.4 %]; and discontinuation due to adverse
events, RR 2.22, 95 % CI 1.08-4.56, p = 0.03, I2 = 0 %;
4 RCTs, 25/342 [7.3 %] vs. 9/342 [2.6 %]. There were
no differences in medication discontinuation overall
or discontinuation due to adverse events between
subgroups of cardiovascular disease, pericarditis, and
post-pericardiotomy or radiofrequency ablation patient
trials (interaction p = 0.16-0.18) (results not shown).) with 95 % confidence intervals (CI) for randomized controlled trials
surgery pericardiotomy, or post radiofrequency (RF) ablation for
ing random-effects models. Weight refers to the contribution of each
orizontal line denotes the point estimate and 95 % CI for each trial’s
point estimate and width denotes the 95 % CI
Fig. 6 Forest Plot for Gastrointestinal Adverse Events. Individual and pooled risk ratios (RR) with 95 % confidence intervals (CI) for randomized
controlled trials (RCTs) comparing colchicine to placebo or control in patients with cardiovascular diseases, pericarditis, and post pericardiotomy
or radiofrequency (RF) ablation. The pooled RRs with 95 % CI were calculated using random-effects models. Weight refers to the contribution of
each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95 % CI for each
trial’s RR. The diamonds signify the pooled RR; the diamond’s centre denotes the point estimate and width denotes the 95 % CI. The pericarditis
patient trials [18–22] which reduced the dose of colchicine for intolerance or low body weight (<70 kg) and enrolled generally younger patients
(mean age 48–57), showed no significant increase in gastrointestinal side effects. This was different than the results from the other trials which showed
a doubling of risk (interaction p = 0.01). Including data from all 7 RCTs that reduced the dose of colchicine for intolerance or body weight <70 kg
[18–22, 24, 25], the increase in gastrointestinal adverse events was lower but still statistically significant (RR 1.56, 95 % CI 1.09-2.24, p = 0.01, I2 = 0 %;
7 RCTs, 1524 patients) suggesting that dose reduction by itself is not sufficient to eliminate gastrointestinal side effects. For two RCTs that reported
non-diarrhea gastrointestinal side effects separately from the diarrhea side effects we assumed that the 5/130 vs. 4/67 patients with nausea or vomiting
and 0/130 vs. 1/67 patients with dyspepsia were different than the 36/130 vs. 3/67 patients with diarrhea [16] and the 6/103 vs. 3/103 patients with
nausea were different than the 10/103 vs. 2/103 patients with diarrhea [27]. Results are similar if one assumes that these events occurred in the same
patients for these 2 RCTs (overall RR 2.11, 95 % CI 1.54-2.89, p < 0.0001, I2 = 26 %; 216/1559 [13.9 %] vs. 77/1463 [5.3 %])
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As suggested by this meta-analysis, in different popula-
tions of patients with established cardiovascular disease,
colchicine reduces the composite cardiovascular
outcome by approximately 60 %. Although the pooled
results are consistent between trials with no heterogen-
eity, the estimates are dominated by one open-label RCT
(though with blinded outcome assessors) enrolling
patients with stable coronary artery disease [14].
Our meta-analysis also demonstrates that colchicine
reduces the rates of pericarditis recurrence, post-peri-
cardiotomy syndrome, and atrial fibrillation post car-
diac surgery or radiofrequency ablation by about
50 %. These pooled results are supported by numer-
ous RCTs providing consistent results. Pooled resultsfrom all RCTs demonstrated that side effects, primar-
ily diarrhea and other gastrointestinal symptoms, are
increased contributing to higher medication discon-
tinuation rates compared to placebo/control groups;
however, no serious adverse events were reported.
Our systematic review and meta-analysis is the first to
include RCTs testing the effect of colchicine in all car-
diac diseases and is the largest and most comprehensive
published to date. Previous reviews have included only
RCTs enrolling patients with pericarditis, or the post
pericardiotomy syndrome [30–34], and even the most
recent of these did not include the most recently
published post pericardiotomy [25] or atrial fibrillation
[25–27] prevention RCTs. A protocol for a systematic
review of colchicine for secondary prevention of
Fig. 7 Forest Plot for All Medication Discontinuation and Discontinuation Due to Side Effects. Individual and pooled risk ratios (RR) with 95 %
confidence intervals (CI) for randomized controlled trials (RCTs) comparing colchicine to placebo or control in patients with various cardiac
conditions. The pooled RRs with 95 % CI were calculated using random-effects models. Weight refers to the contribution of each study
to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95 % CI for each trial’s
RR. The diamonds signify the pooled RR; the diamond’s centre denotes the point estimate and width denotes the 95 % CI. Including
only data from the 7 RCTs that reduced the dose of colchicine for intolerance or body weight <70 kg [18–22, 24, 25], the rates of
medication discontinuation were still increased: discontinuation overall, RR 1.40, 95 % CI 1.04-1.89, p = 0.03, I2 = 0 %; 7 RCTs, n = 1524;
and discontinuation due to adverse events, RR 2.22, 95 % CI 1.08-4.56, p = 0.03, I2 = 0 %; 4 RCTs, n = 684. There were no differences in
medication discontinuation overall or discontinuation due to adverse events between subgroups of cardiovascular disease, pericarditis,
and post-pericardiotomy or radiofrequency ablation patient trials (interaction p = 0.16-0.18) (results not shown)
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Cochrane Collaboration.
Plausible mechanisms have been proposed to explain
the apparently beneficial effects of colchicine for preven-
tion of cardiovascular events [36]. Colchicine has been
shown to inhibit neutrophil chemotaxis, ingress and ac-
tivation within a pro-inflammatory environment. These
anti-inflammatory effects appear to be important for
preventing pericarditis recurrence; however, activated
neutrophils are also present in atherosclerotic plaques
and appear to play a key role in the transformation of a
stable to an unstable plaque. By suppressing neutrophils,
colchicine may play a role in stabilizing plaques and pre-
venting fissuring or rupture that can result in the clinical
manifestations of acute coronary ischemia or stroke. It is
reasonable to speculate that colchicine has greater po-
tential for action in stable coronary disease, where in-
flammatory mechanisms play a major role in diseaseprogression, and that it may have less potential to pro-
vide any benefit in acute coronary syndromes in which
atherothrombosis predominates. This may explain the
large benefit observed in the only RCT that evaluated
colchicine in patients with stable CAD [14], and lower
or absent benefits observed in RCTs trying to prevent
angioplasty induced vascular injury [16], stent-related
disease [7] and acute plaque instability [15], which are
different cardiovascular disease entities with unique
pathophysiology. Numerous additional trials evaluating
the use of colchicine in patients with stable cardiovascu-
lar disease, acute coronary syndrome, atrial fibrillation,
and post operatively are listed on trial registries suggest-
ing that more data regarding colchicine’s effectiveness in
specific cardiovascular conditions will be forthcoming
(Table 4). In addition several other trials of inflam-
mation reduction in secondary prevention of cardio-
vascular events are currently underway, some with
Table 4 Trial Registration Numbers of Ongoing Trials
Stable Cardiovascular Disease
ACTRN12614000093684 - The LoDoCo2 Trial: A randomised controlled
trial on the effect of low dose Colchicine for secondary prevention of
cardiovascular disease in patients with established, stable coronary artery
disease. This study is not yet recruiting. Sponsor: Heart Research Institute
of Western Australia/Aspen Pharmacare Australia. Target enrolment:
3000 patients.
NCT02153983 - Effects of Colchicine in Non-Diabetic Adults With
Metabolic Syndrome. This study is currently recruiting participants.
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD). Target enrolment: 100 patients.
NCT02162303 - Colchicine in Vascular Inflammation Assessed With PET
Imaging (COLPET). This study is currently recruiting participants. Sponsor:
Montreal Heart Institute. Target enrolment: 106 patients.
Acute Coronary Syndrome
NCT01906749 - Colchicine for Acute Coronary Syndromes (COACS). This
study is currently recruiting participants. Sponsor: Maria Vittoria Hospital.
Target enrolment: 500 patients.
NCT01936285 - Colchicine in ST-elevation Myocardial Infarction. This
study is currently recruiting participants. Sponsor: G. Gennimatas General
Hospital. Target enrolment: 75 patients.
NCT02095522 - COlchicine Improve EnDothElial Function in Non ST
Elevation Myocardial Infarction Patients (CODEN). This study is not yet
open for participant recruitment. Sponsor: Tel-Aviv Sourasky Medical
Center. Target enrolment: 100 patients.
Percutaneous Intervention
NCT01709981 - Anti-inflammatory Effects of Colchicine in PCI. This study
is currently recruiting participants. Sponsor: New York University School
of Medicine. Target enrolment: 400 patients.
Post-Operative
ISRCTN72835417. COlchicine for the preVention of postopErative atrial
fibRillation in patients undergoing Coronary Artery By-pass Grafting
(COVER CABG). Completed. Sponsor: Catholic University of the Sacred
Heart-Rome (Italy). Target enrolment: 320 patients.
ACTRN12613001345774 - Colchicine for the Primary Prevention of Atrial
Fibrillation after Cardiac Surgery: A Double Blind Placebo Randomised
Controlled Trial. Recruiting. Sponsor: Barwon Health - The Geelong
Hospital. Target enrolment: 520 patients.
NCT01266694 - Cochicine Treatment for Post- Operative Pericardial
Effusion (POPE2). This study has been completed. Sponsor: French
Cardiology Society. Target enrolment: 199 patients.
NCT01985425 - Colchicine For Prevention of Perioperative Atrial
Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study (COP-AF
Pilot) This study is currently recruiting participants. Sponsor: McMaster
University. Target enrolment: 100 patients.
NCT02122484 - Colchicine in Coronary Artery Bypass Graft (CABG). This
study is ongoing, but not recruiting participants. Sponsor: G.Gennimatas
General Hospital. Target enrolment: 75 patients.
NCT02177266 - Colchicine to Prevent Post-Pericardiotomy Syndrome
and Atrial Fibrillation. This study is not yet open for participant
recruitment. Sponsor: Mayo Clinic. Target enrolment: 242 patients.
Chronic Atrial Fibrillation
NCT01755949 - Impact and Time Course of Colchicine Therapy on
C-reactive Protein Elevation in Chronic Atrial Fibrillation and Post AF
Ablation. This study is currently recruiting participants. Sponsor: Mayo
Clinic. Target enrolment: 60 patients.
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trexate), and others with specific anti-inflammatory
approaches (such as cannakinumab) [37].
This meta-analysis demonstrated that side effects were
minimal; however, the short duration of therapy and follow
up in most of the included RCTs meant that primarily early
side effects, best described as intolerance that leads to early
discontinuation of the medication, were recorded. In appli-
cations requiring only short term use such as pericarditis
and atrial fibrillation prevention there is a need to develop
preparations that address (mostly gastrointestinal) in-
tolerance. In contrast, the use of colchicine for primary
or secondary prevention of cardiovascular events will
require longer term use. Based upon the experience in
the treatment of familial Mediterranean fever, the inci-
dence of late side effects of very long term continuous
use of colchicine doses of up to 2–3 mg/day appear
infrequent [2, 4]; however, these incidences of late side
effects mostly relate to the use in younger people with-
out vascular disease who are not on statins or at risk of
multiple drug use and renal or hepatic dysfunction over
years. Long-term studies in people with cardiovascular
disease will be important in proving the safety of long-
term lower dose therapy in this population.
Study limitations
Although we used rigorous systematic review and
meta-analytic methods consistent with PRISMA guide-
lines including a reproducible and comprehensive lit-
erature search strategy, clearly defined inclusion
criteria, citation review, data abstraction, and quality
assessment of individual studies, and a pre-defined ana-
lysis plan, we pooled results from studies enrolling pa-
tients with a variety of cardiac diseases. Except in the
case of patients with pericarditis, most of the RCTs
enrolled patients with related but non-identical cardio-
vascular diseases (e.g. single or at most two RCTs
enrolled patients with stable CAD, acute coronary syn-
drome or acute stroke, post PTCA, etc.). This illustrates
the paucity of RCT data in patients with cardiovascular
diseases, and limits the ability to draw definitive con-
clusions regarding the effectiveness of colchicine in
non-pericarditis cardiac patients. However, we mini-
mized pooling data from disparate RCTs by including
only RCTs with similar characteristics for specific out-
comes. For example, for the primary outcomes, only
patients in the cardiovascular disease RCTs were
included in the composite cardiovascular event or mor-
tality analyses, and only patients in the pericarditis
RCTs had recurrent pericarditis events. Similarly the
low number of non-gastrointestinal adverse events
limits the ability of our systematic review to rule out in-
creases in other, potentially more serious, adverse
events since the upper limit of the 95 % confidence
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event pooled analyses all included increased risks that
would be clinically significant.
Conclusions
In a wide range of patients with established cardiovascular
disease colchicine reduces the composite rate of adverse
cardiovascular outcomes. Furthermore, colchicine is
associated with a significant reduction in the rates of
recurrent pericarditis, post-pericardiotomy syndrome, and
peri-procedural atrial fibrillation following cardiac surgery
and atrial fibrillation ablation. This suggests that the di-
verse anti-inflammatory effects of colchicine appear to
have benefits in a wide range of cardiovascular dis-
eases. These data support the need for future RCTs
of colchicine especially for the secondary prevention
of cardiovascular disease.
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